JumpStart Ventures Invests $250,000 in Thermalin Diabetes Inc.
03/29/2010
"Over the next 20 years, worldwide insulin sales are expected to grow from $12 billion to $54 billion, JumpStart Ventures partner Ted Frank told Crain's Cleveland Business. "That growth, combined with the medical community's interest in insulin with higher performance, fewer side effects, and storage flexibility, position Thermalin's pipeline to be in high demand."
Thermalin will use the funds to validate its insulin analogs' characteristics, locate a manufacturer, and proceed in the investigational drug process with the FDA.
The company's products include a faster meal-time insulin that is expected to reduce long-term side effects. The insulin can also be stored at higher temperatures, which would make transport and delivery easier.
Project Announcements
Eurofins Lancaster Laboratories Expands Lancaster County, Pennsylvania, Research Operations
01/03/2026
Creative 3D Technologies Expands Cedar Park, Texas, Headquarters-Manufacturing Operations
01/03/2026
Valerie Health Plans Chattanooga, Tennessee, Operations
01/02/2026
Samsung Biologics Plans Rockville, Maryland, Manufacturing Operations
12/31/2025
Kraken Technologies Limited Plans New York City Headquarters Operations
12/29/2025
Lupin Expands Coral Springs, Florida, Operations
12/29/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Data Centers in 2025: When Power Became the Gatekeeper
Q4 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025
-
Supply Chain Whiplash Reshapes CRE
Q3 2025